23 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Jan 2029
Next term end
17
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2032 · High confidence
Also notable
Ends Sep 2029 · High confidence
Also notable
Ends Nov 2030 · High confidence
Methods and Systems for Harvesting Cells
US 9,657,266
The most cited patent in this portfolio, cited by 80 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2032.
Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy
US 8,529,888
Cited by 76 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Adherent Cells from Placenta and Use of Same in Disease Treatment
US 9,175,262
Cited by 60 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Gene and Protein Expression Properties of Adherent Stromal Cells Cultured in 3D (US 10,351,910) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 2 fees due Feb 4 to 27, 2027 · next Feb 4
- 1 fee due May 3, 2027The maintenance fee for Adherent Cells from Placenta and Use of Same in Disease Treatment (US 9,175,262) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for System and Methods for Immune Cells Expansion and Activation in Large Scale (US 11,939,562) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Adherent Cells from Placenta and Use of Same in Disease Treatment (US 10,610,545) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
The 5 largest of its 17 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| System and Methods for Immune Cells Expansion and Activation in Large Scale | 3 in force | to May 2043 |
| Methods and Systems for Harvesting Cells | 2 in force | to Apr 2032 |
| Adherent Cells from Placenta and Use of Same in Disease Treatment | 2 in force | to Nov 2030 |
| Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy | 2 in force | to Sep 2029 |
| Adherent Cells from Placenta Tissue and Use Thereof in Therapy | 2 in force | to Sep 2029 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,517,248 | Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy In force · Low confidence | In force | Low confidence | |
| US 8,524,496 | Adherent Cells from Placenta Tissue and Use Thereof in Therapy In force · High confidence | In force | High confidence | |
| US 9,758,762 | Perfusion Bioreactor for Culturing CD200- Placenta Adherent Cells In force · High confidence | In force | High confidence | |
| US 8,529,888 | Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy In force · High confidence | In force | High confidence | |
| US 9,393,273 | Methods of Treating Inflammatory Colon Diseases In force · High confidence | In force | High confidence | |
| US 9,096,827 | Adherent Cells from Placenta Tissue and Use Thereof in Therapy In force · High confidence | In force | High confidence | |
| US 9,175,262 | Adherent Cells from Placenta and Use of Same in Disease Treatment In force · High confidence | In force | High confidence | |
| US 10,610,545 | Adherent Cells from Placenta and Use of Same in Disease Treatment In force · High confidence | In force | High confidence | |
| US 10,722,541 | Methods for Treating Radiation or Chemical Injury In force · Medium confidence | In force | Medium confidence | |
| US 9,757,419 | Skeletal Muscle Regeneration Using Mesenchymal System Cells In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 1 patent ended · 10 applications pending · 16 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.